During Monday’s Current trade, Shares of Western Refining, Inc. (NYSE:WNR), lost -3.12% to $43.51.
Western Refining, Inc. (WNR) will declare earnings results for the third quarter ended September 30, 2015, on Tuesday, November 3, 2015, before the open of trading on the New York Stock Exchange. The Company has planned a conference call for November 3, 2015, at 10:00 a.m. ET to talk about these results.
Western Refining, Inc. operates as an independent crude oil refiner and marketer of refined products. The company operates in four segments: Refining, NTI, WNRL, and Retail. The Refining segment owns and operates two refineries that process crude oil and other feed stocks primarily into gasoline, diesel fuel, jet fuel, and asphalt; and markets refined products to various customers, counting wholesale distributors and retail chains.
Shares of J M Smucker Co (NYSE:SJM), declined -0.30% to $114.02, during its current trading session.
The J. M. Smucker Company (SJM) (the “Company”) recently declared that it has extended its offer (the “Exchange Offer”) to exchange up to (i) $500,000,000 of its 1.750% Notes due 2018 for an equal principal amount of its outstanding 1.750% Notes due 2018, (ii) $500,000,000 of its 2.500% Notes due 2020 for an equal principal amount of its outstanding 2.500% Notes due 2020, (iii) $400,000,000 of its 3.000% Notes due 2022 for an equal principal amount of its outstanding 3.000% Notes due 2022, (iv) $1,000,000,000 of its 3.500% Notes due 2025 for an equal principal amount of its outstanding 3.500% Notes due 2025, (v) $650,000,000 of its 4.250% Notes due 2035 for an equal principal amount of its outstanding 4.250% Notes due 2035, and (vi) $600,000,000 of its 4.375% Notes due 2045 for an equal principal amount of its outstanding 4.375% Notes due 2045. The Exchange Offer, formerly planned to expire at 5:00 p.m., New York City time, on September 22, 2015, will now expire at 5:00 p.m., New York City time, on September 29, 2015, unless further extended by the Company. All other terms and conditions of the Exchange Offer will remain in full force and effect. The terms and conditions of the Exchange Offer are set forth in the Prospectus dated August 24, 2015 (the “Prospectus”), filed with the U.S. Securities and Exchange Commission, and the related Letter of Transmittal. Questions regardingthe procedure for tendering, in addition to requests for additional copies of the Prospectus and the Letter of Transmittal, may be directed to the Exchange Agent, U.S. Bank National Association, Attention: Corporate Actions, 111 Fillmore Avenue, St. Paul, MN 55107-1402, Telephone: (800) 934-6802.
As of 5:00 p.m., New York City time, on September 22, 2015, about (i) $500,000,000 in aggregate principal amount of the 1.750% Notes due 2018, or 100% of the outstanding notes, (ii) $499,645,000 in aggregate principal amount of the 2.500% Notes due 2020, or 99.93% of the outstanding notes, (iii) $400,000,000 in aggregate principal amount of the 3.000% Notes due 2022, or 100% of the outstanding notes, (iv) $999,979,000 in aggregate principal amount of the 3.500% Notes due 2025, or 99.99% of the outstanding notes, (v) $649,000,000 in aggregate principal amount of the 4.250% Notes due 2035, or 99.85% of the outstanding notes, and (vi) $593,600,000 in aggregate principal amount of the 4.375% Notes due 2045, or 98.93% of the outstanding notes, had been validly tendered and not withdrawn in the Exchange Offer, counting by means of guaranteed delivery.
The J. M. Smucker Company manufactures and markets branded food products worldwide. It operates through four segments: U.S. Retail Coffee; U.S. Retail Consumer Foods; U.S. Retail Pet Foods; and International, Foodservice, and Natural Foods.
Zimmer Biomet Holdings Inc (NYSE:ZBH), during its Monday’s current trading session decreased -2.85% to $91.80.
Zimmer Biomet declared the release of the Subchondroplasty® Procedure for the Foot and Ankle. Since commercialization in 2010, surgeons have performed more than 10,000 Subchondroplasty procedures, mostly on the knee. However, the procedure has been successfully applied to other joints as surgeons witnessed the benefits of treating subchondral bone defects.
According to Erik Nilssen, MD, of The Nilssen Orthopedic Ankle & Foot Center at The Andrews Institute, “Preceding to Subchondroplasty, I had no viable treatment for patients with chronic stress fractures in the foot and ankle. These injuries show up on MRI, are very painful and often fail to heal with conservative treatment.”
The Subchondroplasty Procedure is a minimally invasive outpatient intervention that addresses the defects associated with subchondral bone marrow lesions (BML). Diagnosed using MRI and physical exam, BML are associated with stress fractures or micro-fractures of the bone adjacent to the joint. Left untreated, these defects have been shown to lead to cartilage degeneration, limited function, pain and greater risk for joint deterioration. For more information regarding Subchondroplasty Procedures, please visit www.subchondroplasty.com.
Zimmer Biomet Holdings, Inc., together with its auxiliaries, designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific.
Finally, FMC Corp (NYSE:FMC), decreased -3.75%, to $33.01.
FMC Corporation (FMC) declared that effective October 1, 2015, or as contracts permit, it will enhance prices for its lithium products in all global regions. All products counting lithium carbonate, lithium chloride, lithium hydroxide and all other products except Specialty Organics will enhance by 15 percent. Specialty Organics products, which comprise all grades of butyllithium, will enhance by $3.50 per kilogram on a contained basis. The enhances apply to all standard and non-standard pricing.
FMC Corporation, a diversified chemical company, provides solutions, applications, and products for the agricultural, consumer, and industrial markets in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through three segments: FMC Agricultural Solutions, FMC Health and Nutrition, and FMC Lithium. The FMC Agricultural Solutions segment develops, manufactures, and sells crop protection, professional pest control, and lawn and garden products, such as insecticides, herbicides, and fungicides.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
